LLY vs. RPRX: Eli Lilly vs. Royalty Pharma Stock Comparison
How do Eli Lilly (LLY) and Royalty Pharma (RPRX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Eli Lilly (LLY) and Royalty Pharma (RPRX) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Eli Lilly (LLY) has more than two decades of public-market history since June 1, 1972, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.
| Profile Item | LLY | RPRX |
|---|---|---|
| Name | Eli Lilly and Company | Royalty Pharma plc Class A Ordinary Shares |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 1,206.07 billion USD | 38.70 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 1, 1972 | June 16, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | LLY | RPRX |
|---|---|---|
| Total Return (1Y) | 52.36% | 81.08% |
| Total Return (3Y, Annualized) | 34.18% | 39.21% |
| Total Return (5Y, Annualized) | 41.08% | 14.22% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | LLY | RPRX |
|---|---|---|
| Volatility (1Y, Annualized) | 35.34% | 22.05% |
| Beta (5Y) | 0.40 | 0.36 |
| Max Drawdown (5Y) | -34.48% | -41.98% |
| Avg. Volume (3M) | 2.52M | 3.10M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | LLY | RPRX |
|---|---|---|
| Sharpe Ratio (1Y) | 1.36 | 3.48 |
| Sortino Ratio (1Y) | 2.29 | 5.72 |
Profitability
ROE (TTM)
Both Eli Lilly (LLY) at 86.02% and Royalty Pharma (RPRX) at 12.09% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
86.02%
- Max
- 109.18%
- LLY
- 86.02%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.09%
- Max
- 109.18%
- RPRX
- 12.09%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Eli Lilly (LLY) at 31.90% and Royalty Pharma (RPRX) at 25.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.90%
- LLY
- 31.90%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.70%
- RPRX
- 25.70%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Eli Lilly (LLY) at 53.66% and Royalty Pharma (RPRX) at 81.32% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
53.66%
- Max
- 83.12%
- LLY
- 53.66%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.32%
- Max
- 83.12%
- RPRX
- 81.32%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | LLY | RPRX |
|---|---|---|
| ROE (TTM) | 86.02% | 12.09% |
| ROA (TTM) | 21.06% | 5.43% |
| Net Margin (TTM) | 31.90% | 25.70% |
| Operating Margin (TTM) | 53.66% | 81.32% |
| Gross Margin (TTM) | 83.63% | 99.79% |
Growth
Revenue Growth
Both Eli Lilly (LLY) at 44.70% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Royalty Pharma (RPRX) at 23.09% is closer to the peer norm — faster per-share earnings growth for LLY.
Growth Metrics
| Metric | LLY | RPRX |
|---|---|---|
| Revenue Growth (YoY) | 44.70% | 5.06% |
| Revenue Growth (3Y CAGR) | 31.69% | 2.06% |
| EPS Growth (YoY) | 95.99% | 23.09% |
| EPS Growth (3Y CAGR) | 51.71% | 161.10% |
Financial Strength
Current Ratio (MRQ)
Both Eli Lilly (LLY) at 1.39 and Royalty Pharma (RPRX) at 1.29 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- LLY
- 1.39
- Min
- 0.10
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.29
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- RPRX
- 1.29
- Min
- 0.10
Debt / Equity (MRQ)
Both Eli Lilly (LLY) at 1.23 and Royalty Pharma (RPRX) at 0.88 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.23
- Max
- 1.42
- LLY
- 1.23
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.88
- Max
- 1.42
- RPRX
- 0.88
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | LLY | RPRX |
|---|---|---|
| Current Ratio (MRQ) | 1.39 | 1.29 |
| Debt / Equity (MRQ) | 1.23 | 0.88 |
| Net Debt / EBITDA | 0.96 | 4.76 |
Dividends
Dividend Yield (TTM)
Both Eli Lilly (LLY) at 0.49% and Royalty Pharma (RPRX) at 1.37% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.49%
- LLY
- 0.49%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.37%
- RPRX
- 1.37%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both Eli Lilly (LLY) at 21.71% and Royalty Pharma (RPRX) at 60.46% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.71%
- LLY
- 21.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
60.46%
- RPRX
- 60.46%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | LLY | RPRX |
|---|---|---|
| Dividend Yield (TTM) | 0.49% | 1.37% |
| Dividend Payout Ratio (TTM) | 21.71% | 60.46% |
Valuation
P/E Ratio (TTM)
Both Eli Lilly (LLY) at 43.95 and Royalty Pharma (RPRX) at 43.99 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.95
- Max
- 85.34
- LLY
- 43.95
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.99
- Max
- 85.34
- RPRX
- 43.99
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Eli Lilly (LLY) at 13.95 and Royalty Pharma (RPRX) at 14.79 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.95
- Max
- 58.18
- Q3
- 25.77
- LLY
- 13.95
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.79
- Max
- 58.18
- Q3
- 25.77
- RPRX
- 14.79
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Royalty Pharma (RPRX) at 4.39 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.96
- LLY
- 29.96
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.39
- Max
- 13.53
- Q3
- 6.54
- RPRX
- 4.39
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | LLY | RPRX |
|---|---|---|
| P/E Ratio (TTM) | 43.95 | 43.99 |
| P/S Ratio (TTM) | 13.95 | 14.79 |
| P/B Ratio (MRQ) | 29.96 | 4.39 |
| Free Cash Flow Yield (TTM) | 0.77% | -1.16% |